Page 9 - Immunology_11_2021
P. 9

Multi-Tasking                                              S3


       RAPID Relief









































       S3




         •  Fast-acting olopatadine HCL                 1


         •  Long-acting mometasone furoate
                                                                1

         •  Relieves AR* symptoms
                                                 1

         •  Restores QoL**
                                    2


         •  Optimal control of rhinitis has a beneficial

             effect on asthma (UAD***)
                                                    3

         *Allergic Rhinitis; **Quality of Life; *** United Airways Disease


                                     References: 1. Patel P, Salaptek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal rhinitis symptoms in an environmental exposure
                                     chamber study. American College of Allergy, Asthma & Immunology. 2019;122(2):160-166.e.1. 2. Gross GN, et al. Efficacy and safety of olopatadine-mometasone
                                     combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol, 2019;122:630-638. 3. Donner CF. Inflammation and Infection of the
                                     Upper and Lower Respiratory Tract: United Airways Disease. RT Magazine. https://rtmagazine.com/disorders-diseases/chronic-pulmonary-disorders/asthma/inflammation-
                                     and-infection-in-the-upper-and-lower-respiratory-tract-united-airways-disease/ [Accessed Aug 2021]
                                     S3  RYALTRIS  (Nasal spray). Reg. no. 53/21.5.1/0457. Each spray delivers 600 µg olopatadine (as olopatadine hydrochloride) and 25 µg mometasone furoate (as
                                           ®
                                     mometasone furoate monohydrate). Contains the preservative benzalkonium chloride 0,02 % w/w. Sugar free. For full prescribing information refer to the professional
                                     information approved by the South African Health Products Regulatory Authority. Date of publication: 5 May 2020.
                                     HCR: Glenmark Pharmaceuticals South Africa (Pty) Ltd. 2nd Floor, Building D, Stoneridge Office Park, 8 Greenstone Place, Greenstone, Edenvale, Gauteng, 1609.
                                     (Office) +27 11 564 3900 www.glenmarkpharma.com.             ZAR/08/2021/36

                                       Glenmark, touching the lives of patients for over three decades.




                                                                                                             2021/10/14   12:45
   2021 RYALTRIS MODERN MEDICINE.indd   1                                                                    2021/10/14   12:45
   2021 RYALTRIS MODERN MEDICINE.indd   1
   4   5   6   7   8   9   10   11   12   13   14